These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27868145)

  • 1. Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance.
    Hansel K; Bianchi L; Lanza F; Bini V; Stingeni L
    Acta Derm Venereol; 2017 Mar; 97(3):346-350. PubMed ID: 27868145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study.
    Piaserico S; Gisondi P; De Simone C; Marinello E; Conti A; Amerio P; Peserico A
    Acta Derm Venereol; 2016 Feb; 96(2):251-2. PubMed ID: 26270599
    [No Abstract]   [Full Text] [Related]  

  • 3. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
    Gniadecki R; Leonardi CL; Gordon KB; Gu Y; Geng Z; Nader A; Teixeira HD
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1297-1304. PubMed ID: 29524255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
    Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
    Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
    Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ
    JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
    Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
    Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
    Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility Study.
    van Bezooijen JS; van Doorn MBA; Schreurs MWJ; Koch BCP; Te Velthuis H; Prens EP; van Gelder T
    Ther Drug Monit; 2017 Aug; 39(4):379-386. PubMed ID: 28570371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment.
    Taniguchi T; Noda S; Takahashi N; Yoshimura H; Mizuno K; Adachi M
    J Eur Acad Dermatol Venereol; 2013 Nov; 27(11):1444-7. PubMed ID: 22702802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
    Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution.
    Kamiya K; Karakawa M; Komine M; Kishimoto M; Sugai J; Ohtsuki M
    J Dermatol; 2019 Mar; 46(3):199-205. PubMed ID: 30672612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation.
    Di Lernia V; Bianchi L; Guerriero C; Stingeni L; Gisondi P; Filoni A; Guarneri C; Belloni Fortina A; Lasagni C; Simonetti O; Neri I; Zangrilli A; Moretta G; Hansel K; Casanova DM; Girolomoni G; Cannavò SP; Bonamonte D
    Dermatol Ther; 2019 Nov; 32(6):e13091. PubMed ID: 31579972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C; Kirby B; Collins P; Rogers S
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.
    Menter A; Thaçi D; Papp KA; Wu JJ; Bereswill M; Teixeira HD; Rubant S; Williams DA
    J Am Acad Dermatol; 2015 Sep; 73(3):410-9.e6. PubMed ID: 26190240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
    Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
    J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study.
    Asahina A; Ohtsuki M; Etoh T; Gu Y; Okun MM; Teixeira HD; Yamaguchi Y; Nakagawa H
    J Dermatol; 2015 Nov; 42(11):1042-52. PubMed ID: 26118825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.